Table 2.

List of compounds and targets that are currently in clinical development

Drug	Mechanism of action	Study number	Clinical stage	Indication	Alone or in combination
Reparixin	Reparixin Noncompetitive allosteric inhibitor of CXCR1 and CXCR2 chemokine.	NCT02001974	I	Metastatic Breast Cancer	Paclitaxel + Reparixin
Reparixin	Reparixin Noncompetitive allosteric inhibitor of CXCR1 and CXCR2 chemokine	NCT01861054	II	Metastatic Breast Cancer	Alone
Reparixin	Reparixin Noncompetitive allosteric inhibitor of CXCR1 and CXCR2 chemokine	NCT02370238	II	Metastatic Breast Cancer	Paclitaxel in Combination With Reparixin or Placebo